Trial Profile
Study of GS-6637 for the treatment of cocaine use disorders
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs ANS 6637 (Primary)
- Indications Cocaine-related disorders
- Focus Adverse reactions
- Sponsors Amygdala Neurosciences
- 18 Nov 2019 According to an Amygdala Neurosciences media release, the company has secured $5.6M financing which will be used to fund this trial.
- 18 Feb 2017 New trial record
- 16 Feb 2017 According to a Amygdala Neurosciences media release, the company plans to initiates this study in 2017.